Sesame’s Post

Think #digitalhealth is new? Doina Ionescu makes the case, using oncology as the example, that it’s actually been around since 1879 when the first prescription was made after a phone call (although probably not via FaceTime on an iPhone!). But post #covid, now is the time that health systems really need #pharma companies to lean in and support to improve outcomes across the diagnosis and treatment journey. It’s critical this kind of collaboration continues, despite the challenging economic environment for the industry. NEXT Pharma Summit

Check out my newest IP Bytes blog post about government march-in rights and how its use could potentially reduce the prices of patented drugs. This blog arose from my interest in the material after taking Professor Cynthia Ho's Global Access to Medicine: A Patent Perspective class last spring. Thanks so much to Professor Ho and my IP Bytes editors for helping me get the finished product published! https://lnkd.in/grY98dfc

Maximal Efficacy Unveiled: 🚀 Let's talk maximal efficacy - the top level of a drug's response. Crucial for clinical decisions, especially when a robust response is needed. Dive into a drug's interaction with receptors and the receptor-effector system. #MaximalEfficacy #ClinicalDecisions

Recently, a new class of drug has captured the attention of the media, investors, and customers. Weight loss drugs are not only transforming bodies, but also reshaping fortunes and entire industries. Check out this article to learn more about this trillion-dollar revolution. #ArtemisFactor #HealthcareRevolution #Pharmaceuticals #HealthcareInnovation #WeightLoss #HealthTech #PharmaNews #InvestingInHealth #HealthIndustry

The advantage with Biomimetic Heart Valves

USING MARCH-IN FOR PRICING WILL NOT INFLUENCE PRICE BUT WILL IMPACT THE ECONOMY BUSTED MYTH - The use of marchin-in for price control is a BUSTED MYTH having been tested several times and always yielding the same result - industry walks away from government inventions. Before Bayh Dole, there was the Institutional Patent Agreement (IPA) created by the NIH. It increased patenting (and licensing) by 300% at the NIH in the early 1970s. In 1975, Secretary Joseph Califano suspended the program out of fear of healthcare cost increases (sound familiar?) as it related to CAT scanners - the industry walked away. TEST #1 In 1995, the NIH rescinded its "REASONABLE PRICING" clause from use in the Cooperation Research and Development Agreement (CRADA). NIH Director Harold Varmus stated: “An extensive review of this matter over the past year indicated that the pricing clause has driven industry away from potentially beneficial scientific collaborations with PHS scientists without providing an offsetting benefit to the public….” TEST #2 In 2016 Sanofi walked away from developing the Army's Zika vaccine arising from public pressure by Congress and spurred by NGOs. TEST #3 Reasonable pricing is VAGUE. Who defines it? How? Industries are walking away from government-funded innovation given the drum beating by some in Congress, making it harder for start-ups to get VC funding in a difficult funding climate. Bayh-Dole helped bring the country out of the 1970s stagflation. Don't kill the Golden Egg Laying Goose and remember your history. #BayhDole Joseph Allen Senator Thom Tillis Christopher Coons #AmericanInnovation #InnovationEngine Tom Irving Emily Johnson Corey Salsberg #RepeatingHistory IPWatchdog, Inc Gene Quinn

Thoughts on this? >> SIGA fires former NYC Covid advisor after secret recordings detail pandemic-era parties >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharmaceutical #pharma

𝐍𝐞𝐰 𝐩𝓪𝓹𝓮𝓻 𝓐𝓵𝓮𝓻𝓽: Our latest work targets FDA's 510(k) medical device approval pathway. We show how FDA can hugely benefit from a 𝐡𝐮𝐦𝐚𝐧-𝐚𝐥𝐠𝐨𝐫𝐢𝐭𝐡𝐦 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 trained on its own data sets. The impact? We estimate it would result in between $2.4 billion and $2.7 billion in annual cost-savings. 👇👇👇 #FDA #MedicalDevices #Analaytics

Thoughts on this? >> SIGA fires former NYC Covid advisor after secret recordings detail pandemic-era parties >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #healthcare #biotech

J&J in talks to buy Shockwave Medical, WSJ reports A deal could be finalized in the coming weeks if talks don't fall apart and it is also possible another suitor could emerge, the report said, citing people familiar with the matter. It did not mention the value of the deal. #JohnsonJohnson | #ShockwaveMedical | #CardiovascularDevices | #WallStreetJournal | #Healthnews Read more: